KLOW 80mg Blend

Description

KLOW 80mg peptide blend, documented component by component

Purity Collective supplies the KLOW 80mg Peptide Blend in a lyophilized vial for qualified laboratory research. The catalog formulation lists four reference materials: BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg and KPV 10mg. This page brings the formulation, SKU and available analytical records together so a purchasing team can review what is listed before checkout.

A multi-component blend needs more careful documentation than a single-compound listing. The 80mg catalog total is the sum of the four listed specifications. The attached UPLC/MS report provides a separate quantity and purity result for each submitted component sample; it does not state one blend-wide purity percentage. Those numerical results remain tied to the report and lot shown below.

KLOW 80mg composition and catalog details

• Catalog total: 80mg across four listed components
• Format: Lyophilized vial
• SKU: PC-KLOW-80MG
• UPLC/MS lot: PCCL-7964352
• Endotoxin document lot: PCCL-7964352-E

Review the KLOW analytical documents

Open the complete KLOW 80mg component UPLC/MS report and the separate KLOW 80mg endotoxin document. Purity Collective’s guide to reading a peptide COA explains how to compare identity, lot, method, specification, dates and results without extending a sample result beyond its record.

The eight-page UPLC/MS report identifies lot PCCL-7964352 and presents a dedicated panel for each listed component. The table above transcribes its component-specific quantity and purity results. Each panel prints a purity specification of at least 98%. The report records March 29, 2026 as the analysis date and March 30, 2026 as the received date, placing the stated analysis one day before receipt.

The separate endotoxin document identifies the four-component KLOW formulation under related lot PCCL-7964352-E and records a result below 0.05 EU/mL. It prints April 3, 2026 as the analysis date and April 8, 2026 as the received date, placing the stated analysis five days before receipt. The document does not print an endotoxin acceptance specification, so this page does not label the result a pass or infer sterility, safety, suitability or performance.

Compare the components without transferring evidence

Purity Collective also lists BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg and KPV 10mg as standalone catalog products. Those pages may help a buyer compare names, quantities and formats, but their attached reports belong to different products and lots. Standalone evidence must not be used to characterize this KLOW blend. For public KPV identity context and standalone-versus-blend review, read the KPV research records and KLOW blend review guide. To compare KLOW with the related three-component blend, read the GLOW peptide blend research records and component review guide.

Before you order KLOW 80mg

• Confirm that the four-component formulation and SKU PC-KLOW-80MG match the procurement request.
• Review all eight UPLC/MS pages and the separate endotoxin document, including their lot identifiers and dates.
• Keep each quantity and purity measurement tied to its named component and submitted sample.
• Record both analysis-before-receipt date sequences and the absence of a printed endotoxin acceptance specification.
• Apply your laboratory’s own supplier-qualification, acceptance, storage and handling procedures.

KLOW 80mg peptide blend FAQs

What is in the KLOW 80mg peptide blend?

The catalog formulation lists BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg and KPV 10mg, for a listed total of 80mg in one lyophilized vial.

Does KLOW 80mg have one blend-wide purity result?

No single blend-wide purity percentage is stated in the attached report. It presents separate purity results for BPC-157, TB-500, GHK-Cu and KPV. Each result should stay associated with its component panel and submitted lot.

Which KLOW analytical documents can I review?

The page links directly to an eight-page component UPLC/MS report and a separate endotoxin document. Review both complete files, including the methods, lot identifiers, dates, specifications and results.

What document limitations should a buyer record?

The UPLC/MS report lists analysis one day before receipt, while the endotoxin document lists analysis five days before receipt. The endotoxin document also contains no printed acceptance specification. Purity Collective preserves those details for qualified review.

Is the KLOW peptide blend intended for human use?

No. KLOW 80mg is supplied only for qualified laboratory research and is not for human or veterinary administration. Purity Collective does not provide clinical, therapeutic, dosing or administration guidance.

Research-use notice

For qualified laboratory research only. Not for human or veterinary administration. This listing is not presented as a medicine or treatment.